For the first time, the US Food and Drug Administration has granted de novo marketing authorization for a game-based digital treatment aimed at children with attention deficit hyperactivity disorder (ADHD). It’s not just the first gaming treatment for ADHD – it’s also the first game-based treatment for any condition to get the nod from the FDA, which opens the door for similar therapies.
Boston-based Akili Interactive’s EndeavorRx video game treatment received the marketing authorization to treat children aged 8 to 12 who suffer from ADHD, a 15 June FDA notice says